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Background: Bladder cancer is a relatively common and potentially life-threatening neoplasm that ranks ninth in
terms of worldwide cancer incidence. The aim of this study was to determine deletions and sequence variations in
the mitochondrial displacement loop (D-loop) region from the blood specimens and tumoral tissues of patients
with bladder cancer, compared to adjacent non-tumoral tissues.
Methods: The DNA from blood, tumoral tissues and adjacent non-tumoral tissues of twenty-six patients with
bladder cancer and DNA from blood of 504 healthy controls from different ethnicities were investigated to deter-
mine sequence variation in the mitochondrial D-loop region using multiplex polymerase chain reaction (PCR), DNA
sequencing and southern blotting analysis.
Results: From a total of 110 variations, 48 were reported as new mutations. No deletions were detected in tumoral
tissues, adjacent non-tumoral tissues and blood samples from patients. Although the polymorphisms at loci 16189, 16261
and 16311 were not significantly correlated with bladder cancer, the C16069T variation was significantly present in patient
samples compared to control samples (p < 0.05). Interestingly, there was no significant difference (p > 0.05) of C variations,
including C7TC6, C8TC6, C9TC6 and C10TC6, in D310 mitochondrial DNA between patients and control samples.
Conclusion: Our study suggests that 16069 mitochondrial DNA D-Loop mutations may play a significant role in
the etiology of bladder cancer and facilitate the definition of carcinogenesis-related mutations in human cancer.
Keywords: Mitochondrial DNA displacement loop, 16069 D-Loop mutation, Urinary bladder neoplasmIntroduction
Human mitochondrial DNA (mtDNA) is a 16569-bp
closed circular, double-stranded molecule approximately
1000 copies per cell. mtDNA contains 37 genes, includ-
ing 13 subunits involved in the electron transport chain,
22 tRNAs, the 12S and 16S rRNAs, and a non-coding
region (D-loop) located at nucleotide position 16024–
576 (MITOMAP, 2011) [1]. The D-loop region regulates
the replication and transcription of mtDNA, where* Correspondence: massoudh@nigeb.ac.ir
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distribution, and reproduction in any mediummutations in this region might lead to copy number
and/or change in mtDNA gene expression [2].
Bladder cancer is the ninth most common cancer
worldwide [3]. According to the latest American Cancer
Society statistics, bladder cancer accounts for 7% of all
cancers and 3% of all cancer deaths [4,5]. In Iran, blad-
der cancer accounts for 7.04% of all cancers [6].
Many attempts have been made to develop an urothelial
cancer biomarker test to complement or replace urine cy-
tology, including NMP22, BTA stat, BTATRAK, and FISH.
Most studies on the molecular genetics of the bladder can-
cer focus on changes in genomic DNA, including onco-
genes and tumor suppressor genes, such as HRAS, ERBB2,
TP53 and RB, and subsequent cellular events [7,8].ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.






1 62 Carcinoma in situ+
2 60 Papilloma
3 58 Papillary Urothelial carcinoma- low grade
4 63 Neoplasm of low malignant potential Papillary urothelial
5 73 Carcinoma in situ+
6 80 Papillary urothelial carcinoma – high grade
7 69 Papillary Urothelial carcinoma- low grade
8 68 Neoplasm of low malignant potential Papillary urothelial
9 53 Non-papillary urothelial carcinoma –high grade
10 55 Papillary urothelial carcinoma – high grade
11 75 Non-papillary urothelial carcinoma –high grade
12 78 Papillary Urothelial carcinoma- low grade
13 73 Neoplasm of low malignant potential Papillary urothelial
14 69 Papillary Urothelial carcinoma- low grade
15 68 Non-papillary urothelial carcinoma –high grade
16 57 Neoplasm of low malignant potential Papillary urothelial
17 53 Non-papillary urothelial carcinoma –high grade
18 50 Papillary urothelial carcinoma – high grade
19 49 Papillary Urothelial carcinoma- low grade
20 45 Non-papillary urothelial carcinoma –high grade
21 29 Papillary urothelial carcinoma – high grade
22 70 Papillary Urothelial carcinoma- low grade
23 66 Non-papillary urothelial carcinoma –high grade
24 58 Papillary urothelial carcinoma – high grade
25 59 Papillary Urothelial carcinoma- low grade
26 74 Neoplasm of low malignant potential Papillary urothelial
Table 2 Primers used for detection of four deletions
Forward Start point of primer Reversed End
ONP 86: 5461–5480 ONP 74: 15260
5′-CCCTTACCACGCTACTCCTA -3′ 5′-TGTCTACTG
ONP 86: 5461–5480 ONP 10: 13640
5′-CCCTTACCACGCTACTCCTA -3′ 5′-GTTGACCTG
ONP 25: 8161–8180 ONP 10: 13640
5′-CTACGGTCAATGCTCTGAAA-3′ 5′-GTTGACCTG
ONP 25: 8161–8180 ONP 99: 16150
5′-CTACGGTCAATGCTCTGAAA-3′ 5′-GTGGTCAAG
ONP 86: 5461–5480 ONP 89: 5740–
5′-CCCTTACCACGCTACTCCTA -3′ 5′-GGCGGGAG
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http://www.cancerci.com/content/13/1/120Mitochondrial function and DNA attract less interest
in studies on bladder carcinoma. Mitochondrial dysfunc-
tion has been linked to a wide range of degenerative and
metabolic diseases, cancer, and even aging. mtDNA,
which has a very high mutation rate, results in three
classes of clinically relevant phenotypes: deleterious
germline mtDNA mutations, which are linked to mito-
chondrial diseases; mtDNA polymorphisms, which are
related to environmental adaptation in human evolution;
and mtDNA somatic mutations, which are associated
with aging and cancer. Mitochondrial defects were first
associated with carcinogenesis several decades before,
when Warburg reported “injury of the respiratory chain”
and high glycolytic rate as typical of cancer [9-12].
Mitochondrial DNA is thought to accumulate more
mutations than nuclear DNA (nDNA) to some extent,
because the protective histones as well as the highly effi-
cient DNA repair mechanisms do not exist in the mito-
chondrial nucleus. Certain tumors have been shown to
result from mutations in nDNA-encoded mitochondrial
proteins, which may result in increased reactive oxygen
species (ROS) production. Mitochondrial dysfunction
does appear to be a factor in cancer etiology. Alterations
in mitochondrial DNA (mtDNA), including point muta-
tions, deletions, insertions and genome copy number
changes, are believed to be responsible for carcinogen-
esis [13-15]. For example, many reports have identified a
mtDNA 4977-bp deletion in lung [16], breast [17] and
endometrial carcinomas [18].
The use of mtDNA mutation and/or polymorphism
patterns as a biomarker is rapidly expanding in disci-
plines, ranging from rare metabolic diseases and aging
to cancer and the tracing of human migration patterns,
population characterization and human identification in
forensic science. In this study, we examined the presence
of mutations in the mitochondrial D-Loop sequences of
tumoral tissues as compared with adjacent non-tumoral
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*Indicates novel mutation has not been reported before.
Figure 1 Multiplex-PCR amplification. Lanes 1, 2, 3 and 5 show the inter
100 bp DNA size marker. No other bands were observed. Amplification onl
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http://www.cancerci.com/content/13/1/120Materials and Methods
Twenty-six men with primary urothelial bladder cancer
with a mean age of 62.5 years were enrolled in this study
(Table 1). The patients’ written consent was obtained and
the institutional review board approved this study. Tu-
moral tissues were obtained from transurethral resection
of the bladder tumor (TURBT) or radical cystectomy
specimens. Tumoral tissues and adjacent non-tumoral tis-
sues were immediately frozen in liquid nitrogen and kept
at −80°C, while blood samples from patients were ob-
tained before surgery.
Urothelial bladder cancer diagnosis was done via
histological analysis. Blood samples from healthy con-
trols with a mean age of 57.5 years were obtained from
404 individuals of 17 ethnicities and 100 random indi-
viduals, all from the Tehran Special Medical Center. The
exclusion criterion for the control group was any history
of cancer, metabolic diseases and mitochondrial DNA
related diseases that may affect the mtDNA. Ethics ap-
proval and patient informed consent including consent
to participate in the study and consent to publish was
obtained for the present study in accordance to the
Tehran Special Medical Center and Medical Ethics
Committee (Approval No. MS-16-2007).
DNA extraction and sequencing
Genomic DNA (DNA fast, QIAGEN, Cat. No. 51204)
was isolated from the tumoral tissues, adjacent non-
tumoral tissues and blood samples of patients, as well as
from the blood samples of controls, according to the
manufacturer’s protocol. Two pairs of primers designed
to amplify the mtDNA D-loop region are as follows:
ONP 98 F )1579-15810(: 5′-ATC ATT GGA CAA GTAnal control (279 bp), lane 4 is the negative control and lane M is a
y takes place if deletions occur in the DNA between the PCR primers.
Figure 2 Long range PCR amplification of mtDNA using Phusion Flash high-fidelity PCR Master Mix, Thermo Scientific. A two-step long-
range PCR was carried out on the major arc of the mitochondrial genome using the Expand Long Template PCR System to detect mitochondrial
deletions. DNA products were separated using a 0.7% agarose gel containing ethidium bromide and viewed under UV light. Lanes 1 and 3:
negative control; Lanes 2 and 4: an amplified 11 Kb fragment, indicating no deletions were observed in mtDNA; lane M: 1 kb DNA ladder marker.
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http://www.cancerci.com/content/13/1/120GCA TC -3′ and ONP 79R )780-761(: 5′-GAG CTG
CAT TGC TGC GTG CT-3′. Polymerase chain reaction
(PCR) was carried out with the following protocol: pre-
denaturation at 95°C for 5 min, then 35 cycles of 94°C
for 30 sec, 60°C for 45 sec and 72°C for 1 min, and a
final extension step of 72°C for 6 min. Each amplified
fragment was purified using a Agarose Gel DNA Frag-
ment Recovery Kit, Ver.2.0 (TaKaRa, Japan) and subse-
quently sequenced using a ABI PRISM 3730 sequence
analyzer (gene Fanavaran, Macrogene Seoul, Korea). The
quality of the obtained chromatograms was assessed by
FinchTV® software Version 1.4.0 (Geospiza, Inc., USA).Figure 3 Southern blot analysis of mitochondrial DNA (mtDNA) diges
with a DIG-labeled probe. Lanes 1–5 shows intact mtDNA (~16.6 Kb).Multiplex PCR
The PCR reactions were performed for 35 cycles of the
following steps: 94°C for 10 min, 55°C for 10 min, and
72°C for 35 sec. Using the primers ONP 86, ONP 89,
ONP 10, ONP 74, ONP 25 and ONP 99, the deletion-
prone region between 5461 nt of the light strand and
15000 nt of the heavy strand was investigated in all the
patients. The distances between the primers were long
enough to allow amplification only if a part of the DNA
between each respective primers was deleted. As a con-
trol in PCR analysis, a normal internal mtDNA fragment
in a region which is seldom affected by deletions wasted with the restriction enzyme BamH1 (nt14258), and hybridized
Figure 4 Chromatogram showing homoplasmy at position 16069 of the mitochondrial DNA D-loop in a normal sequence (Figure 4-A)
and a variation (Figure 4-B). The arrow marks the sequence variations.
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http://www.cancerci.com/content/13/1/120amplified using the primer pair of ONP 86 and ONP 89
(Table 2). Polymerase chain reaction products were sepa-
rated on 2% agarose gels and run in 0.5× Tris/Borate/
EDTA buffer at 110 V for 50 min, stained in 0.002 μg/mL
ethidium bromide, and visualized by means of an ultravio-
let light.Southern blot analysis
Extracted mtDNA was eletrophoresed on 1% agarose
gel. After electrophoresis, the DNA were denatured,
neutralized and transferred to nylon membrane. Mean-
while, the ONP98 primer (5′-ATCATTGGACAAGTAG
CATC-3′), located at 15791–15810 bp, and the ONP79
Table 4 Comparison of 4 common variations in bladder
cancer patients and controls
Ethnicity NO. 16069 16189 16261 16311
Arab 23 0 (0%) 7 (30.4%) 4 (17.4%) 4 (17.4%)
Armenian 18 0 (0%) 5 (27.7%) 2 (11%) 3 (16.7%)
Asurian 19 1 (5.2%) 7 (36.8%) 3 (15.8%) 1 (5.3%)
Azari 22 0 (0%) 6 (27.3%) 0 (0%) 4 (18.2%)
Turkmen 37 1 (2.7%) 5 (13.5%) 1(2.7%) 6 (16.2%)
Baluch 13 0 (0%) 2 (15.4%) 1 (7.7%) 0 (0%)
Bandari 31 0 (0%) 13 (42%) 2 (6.5%) 5 (13.5%)
Guilani 24 0 (0%) 2 (8.3%) 3 (12.5%) 3 (12.5%)
Jews 37 1 (2.7%) 6 (16.2%) 4 (10.8%) 4 (10.8%)
Kurd 24 2 (8.3%) 3 (12.5%) 4 (16.7%) 6 (25%)
Lur 22 0 (0%) 1 (4.5%) 8 (36.4%) 8 (36.4%)
Mazani 23 0 (0%) 4 (17.4%) 4 (17.4%) 1 (4.3%)
Persian Isfahan 16 0 (0%) 6 (37.5%) 2 (12.5%) 5 (31.2%)
Persian Kerman 25 0 (0%) 7 (28%) 1 (4%) 5 (20%)
Persian Mashhad 23 0 (0%) 5 (21.7%) 2 (8.7%) 2 (8.7%)
Persian Shiraz 23 0 (0%) 4 (17.4%) 2 (8.7%) 3 (3.2%)
Persian Yazd 24 0 (0%) 5 (20.8%) 1 (4.1%) 2 (8.3%)
Mixed Tehran 100 8 (8%) 9 (9%) 9 (9%) 12 (12%)
Total (controls) 504 13 (2.6%) 95 (18.8%) 53 (10.5%) 78 (15.5%)
Patients 26 5 (19%)* 4 (15.4%) 4 (15.4%) 8 (31%)
*Shows statistically significant, p < 0.05.
Table 5 Association of the mtDNA D310 variation in
bladder cancer patients and controls
Ethnicity NO. C 7TC6 C 8TC6 C 9TC6 C 10TC6
Arab 23 12 (52.2%) 8 (34.7%) 2 (8.7%) 1 (4.3%)
Armenian 18 7 (38.9%) 11 (61.1%) 0 (0%) 0 (0%)
Azari 22 8 (36.4%) 12 (54.5%) 2 (9%) 0 (0%)
Turkmen 37 17 (45.9%) 16 (43%) 4 (10.8%) 0 (0%)
Bandari 31 10 (32%) 15 (48.4%) 6 (19.4%) 0 (0%)
Persian Isfahan 16 5 (31.3%) 9 (56.3%) 2 (6.5%) 0 (0%)
Persian Mashhad 23 14 (60.9%) 8 (34.8%) 1 (4.3%) 0 (0%)
Persian Shiraz 23 6 (26%) 16 (69.6) 1 (4.3%) 0 (0%)
Persian Yazd 24 9 (37.5%) 9 (37.5%) 5 (20.8%) 1 (4.1%)
Guilani 24 8 (33%) 12 (50%) 4 (16.6%) 0 (0%)
Jews 37 16 (43%) 17 (45.9) 4 (10.8%) 0 (0%)
Kurd 24 3 (12.5%) 14 (58%) 7 (29%) 0 (0%)
Lur 22 9 (41%) 9 (41%) 4 (18%) 0 (0%)
Total (controls) 324 124 (38.3) 156 (48.1%) 42 (13%) 2 (0.6%)
Patients 21 9 (42.9%) 10 (47.6%) 2 (9.5%) 0 (0%)
The D310 sequence variations of mtDNA in patients and controls were not
significantly different (p > 0.05).
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at 780–761 bp of the mtDNA, were used to amplify a
1558-bp fragment from the D-loop region. This fragment
was used as a mtDNA probe. Southern blot analysis was
performed using the DIG DNA Labeling and Detection
Kit (Cat. #11093657910, Roche).
Statistical analysis
Sequences were edited and aligned using ClustalX. The
revised Cambridge Reference Sequence was used as a
reference (GI: 251831106) (MITOMAP, 2009). The Chi-
square test was used with SPSS (Statistical Package for
the Social Sciences, version: 13) to examine the associ-
ation of variations with control and patient samples.
P-values < 0.05 were regarded as statistically significant.
Results
Samples from a total of 26 patients with sporadic bladder
cancer were screened for mitochondrial deletions and var-
iations. Sequence analysis found a total of 110 variations
(Cambridge Mitochondrial Sequences), of which 62 muta-
tions were previously reported (MITOMAP). However, 48
of these mutations were reported as new mutations, which
are summarized in Table 3. In this study, almost all of the
variations were homoplasmic, but in 6 (16.6%) cases, a C
nucleotide insertion was seen in locus 16194. No mito-
chondrial deletions were found in the patient samples
(Figures 1 and 2), as confirmed by Southern blotting
(Figure 3).
Four common variations, 16069, 16189, 16261 and
16311, were found in the tumoral tissues, adjacent non-
tumoral tissues and blood samples of both patients and
controls from different ethnicities. The polymorphisms
at 16189, 16261 and 16311 were not significantly corre-
lated with bladder cancer. However, the D-loop C16069T
polymorphism (Figure 4) was significantly correlated with
bladder cancer (P < 0.05). Analysis of control samples by
ethnicities for these 4 variations is summarized in Table 4.
No significant difference (p > 0.05) in D310 C variations
was observed between the patient and control samples
(Table 5).
Discussion
Our sequencing analysis focused on the mtDNA D-loop
region, which is highly polymorphic and contains two
hypervariable regions, HV1 (16024–16383) and HV2
(57–333), that was considered as a somatic mutation
“hot spot” in many types of cancer [19]. In this study, no
deletions were seen in the mitochondrial genome. One
hundred and sixteen variations were observed in the D-
Loop region, where 48 of them were not previously re-
ported. Wada et al. [20] also reported that the majority
of somatic mutations were homoplasmic, suggesting that
the mutant mtDNA became dominant in tumor cells.
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http://www.cancerci.com/content/13/1/120Fliss et al. [21] screened 14 urinary bladder cancers for
somatic mutations in the D-loop region, and found mu-
tations in 4 (29%) samples.
Polymorphism 16189, which is highly polymorphic,
was the previous focus of oncological research because
carriers with the T16189C polymorphism were appar-
ently more susceptible to breast cancer and ganglioma
development. Interestingly, the T16189C polymorphism
was found in 14% of endometrial cancers [22] and type
II diabetes mellitus [23,24].
In this study, in contrast to 16189, 16194, 16261 and
16311 variations, the C16069T polymorphism of the D-
loop indicated significant correlation with bladder cancer
(P < 0.05), which has not been studied in bladder cancer
before. However, the C16069T polymorphism has been
reported in prostate cancer [25], pancreatic cancer [26],
endometrial cancer [27], breast cancer [28,29], repeated
pregnancy loss [30] and age-related macular degener-
ation [31]. This result supports our hypothesis, which
shows the potential of specific mitochondrial 16069
polymorphism involvement in carcinogenesis.
Many studies reported that the C150T polymorphism
is correlated with longevity (MITOMAP, 2009). The pos-
sible function of the C150T transition was investigated
in a previous study [32], suggesting that the C150T tran-
sition functions in remodeling mtDNA replication. How-
ever, in our study, no significant differences were found
between C150T mutations in patients and control sam-
ples from different ethnicities.
Large-scale mtDNA deletions have been demonstrated
in several cancers. Kamalidehghan et al. [33] found that
the common mtDNA4977 deletion was less frequent in
gastric cancer tissues compared to the normal adjacent
tissues. While in another study, a deletion of approxi-
mately 8.9 kb was more frequent in gastric carcinoma
tissues than adjacent normal tissue samples [34]. How-
ever, in the present study, no deletions were detected in
bladder carcinoma tissues nor adjacent non-tumoral tis-
sues. Therefore, the pattern of mitochondrial deletions
may differ among different carcinomas.
Marchington et al. [35] first used the term D310 to de-
scribe a highly polymorphic mononucleotide tract of
poly (C) that varies from 12 to 18 Cs, located between
nucleotide positions 303 and 318 in CSB II, that forms a
RNA–DNA hybrid known as an R-loop. This poly(C) re-
gion is interrupted at nucleotide position 310 by a T
(CCCCCCCTCCCCC), in which the number of Cs
before the T can vary between 7 to 9 in normal poly-
morphic variants [35]. D310 has been reported as a
mutational hot-spot in a large panel of tumors includ-
ing gastric, head and neck, breast, colorectal, lung and
bladder cancers, where head and neck cancer has the
highest rate of D310 variants (37%), followed by breast
(29%) and colorectal (28%) cancers. However, no D310alterations were detected in prostate and ovarian can-
cers [36,37].
The D310 region of mtDNA plays an important role
in mitochondrial biogenesis, where somatic insertions or
deletions of one or two base pairs in this region are
thought to have negligible effects on cancers. However,
major deletions or insertions of up to ten bases in the
D310 region could interfere with mtDNA biogenesis
[38]. Mutations in the D-loop, mostly at D310, have been
found in 21% of all head and neck squamous cell carcin-
omas [39]. However, in our study, the D310 mtDNA se-
quence variations, including C7TC6, C8TC6, C9TC6 and
C10TC6, were not significantly different (p > 0.05) be-
tween bladder cancer patients and controls of different
ethnicities.
In conclusion, our study suggests that the mitochon-
drial DNA D-Loop 16069 mutation may play a signifi-
cant role in the etiology of bladder cancer and facilitate
the definition of carcinogenesis-related mutations in hu-
man mtDNA.
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